ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Valproic Acid

Also written as “Divalproex Sodium”, “divalproex sodium” and “Sodium valproate”.

Its studies are mostly in Bipolar Disorder · Epilepsy · Migraine Disorders · Seizures · Schizophrenia, led by 11 companies.

Drug pageValproic Acid: every studyMany companies study it; this page follows only the 38 they lead. All 261 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 15, 200338 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbottits history only100 open or runningphase 3since May 15, 2003May 15, 2003none ahead
Dr. Reddy's Laboratoriesits history only70 open or runningphase 1since Jan 25, 2010Jan 25, 2010none ahead
Sanofiits history only40 open or runningphase 4since Dec 9, 2005Dec 9, 2005none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
AstraZenecaits history only30 open or runningphase 4since Aug 29, 2005Apr 9, 2004none ahead
Novartisits history only30 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Desitin Arzneimittelits history only20 open or runningphase 1since Dec 21, 2023Dec 21, 2023none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Cerebral Therapeutics10 open or runningphase 2since Sep 3, 2016Sep 3, 2016none ahead
Hearthstone Alzheimer Careits history only10 open or runningphase 1since Sep 12, 2005Sep 12, 2005none ahead

Also a collaborator on its studies: BioPharma Services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cerebral Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2016First study: phase 2 study in EpilepsyFirst studyNCT02899611 · 6 enrolled · Australia

TargetBeta

ALDH5A1 →read by rule
“Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

The one study Cerebral Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02899611Epilepsy · Australia2CompletedJun 1, 20216

How it is read

Names in the registry

  • “Divalproex Sodium”, 10 entries
  • “divalproex sodium”, 7 entries
  • “Sodium valproate”, 3 entries
  • “Valproic Acid”, 2 entries
  • “Valproic Acid 500 MG”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.